Compare CRNX & FITBO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRNX | FITBO |
|---|---|---|
| Founded | 2008 | N/A |
| Country | United States | United States |
| Employees | N/A | 18616 |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | N/A |
| IPO Year | 2018 | N/A |
| Metric | CRNX | FITBO |
|---|---|---|
| Price | $37.81 | $19.59 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $74.78 | N/A |
| AVG Volume (30 Days) | ★ 824.8K | 16.2K |
| Earning Date | 06-01-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,039,000.00 | N/A |
| Revenue This Year | $730.30 | N/A |
| Revenue Next Year | $179.48 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $24.10 | $19.19 |
| 52 Week High | $57.99 | $22.80 |
| Indicator | CRNX | FITBO |
|---|---|---|
| Relative Strength Index (RSI) | 32.57 | 44.51 |
| Support Level | $33.23 | $19.20 |
| Resistance Level | $45.32 | $19.85 |
| Average True Range (ATR) | 1.86 | 0.15 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 24.62 | 34.92 |
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.
Fifth Third Bancorp is a midsize regional bank in the US, with total assets of over $210 billion as of December 2025. The bank is set to close its acquisition of Comercia on Feb. 1, 2026. Headquartered in Cincinnati, Ohio, Fifth Third has a strong presence in the US Midwest and is currently expanding in the US Southeast. The bank provides a diversified set of financial services in retail banking, commercial banking, card and Treasury management, wealth and asset management, and capital markets.